Skip to main content
. 2020 Jul 7;11:1406. doi: 10.3389/fimmu.2020.01406

Figure 5.

Figure 5

Tofacitinib alters the NOX2/5 balance in PsA and RA patients. Monocytes from HC, PsA or RA patients were differentiated for 7 days with GM-CSF/IL-4 in presence or absence of Tofacitinib 1 μM (or DMSO). Proteins were isolated and western blot for NOX2, NOX5, and B-actin was performed. (A) Representative western blots for NOX2, NOX5, and B-actin. (B) ROS production in monocytes from PsA (n = 3) and RA (n = 3) patients differentiated for 48 h and stimulated with 1 μM Ionomycin in the presence or absence of Tofacitinib 1 μM (or DMSO) (Kruskal-Wallis test **p < 0.01 ***p < 0.001 DMSO vs. IONO, ###p < 0.001 IONO vs. IONO+TOFA- HC is shown in Supplementary Figure 4B). (C–E) HC Mo-DC were stimulated with CEL (1 and 2 μM-NOX5 inhibitor) and TAT (15 μM-NOX2 inhibitor) 5 min before Tofacitinib treatment 1 μM (C–E) and 0.5 μM (F–H). (C,F) Representative histograms. (D,G) Average of HC n = 3 (Mean ± SEM) separate experiments. (E,H) Representative Contour Plots gating CD209 low (CD209l) and CD209 high (CD209h) populations. Data are represented as Mean ±SEM. One-Way ANOVA *p < 0.05, **p < 0.01, ***p < 0.001 (differences between Mo-DC with and without TOFA within the same group).